MyFinsight
Home
Blog
About
Cash and cash
equivalents
$60,816K
(13.87%↑ Y/Y)
Accounts receivable, net
$56,041K
(40.43%↑ Y/Y)
Short-term investments
$34,513K
(-37.22%↓ Y/Y)
Prepaid and other
current assets
$19,792K
(18.63%↑ Y/Y)
Inventories
$14,367K
(37.84%↑ Y/Y)
Deferred income tax asset
$238,068K
Total current assets
$185,529K
(5.78%↑ Y/Y)
Intangible assets, net
$93,878K
(262.13%↑ Y/Y)
Other assets
$2,944K
(-29.64%↓ Y/Y)
Operating lease
right-of-use assets
$647K
(-45.08%↓ Y/Y)
Total assets
$521,066K
(152.04%↑ Y/Y)
Total liabilities and
stockholders equity
$521,066K
(152.04%↑ Y/Y)
Total stockholders
equity
$425,422K
(419.23%↑ Y/Y)
Total liabilities
$95,644K
(-23.36%↓ Y/Y)
Accumulated deficit
-$997,097K
(24.41%↑ Y/Y)
Accumulated other
comprehensive (loss) income
-$148K
(-2566.67%↓ Y/Y)
Additional paid-in capital
$1,422,649K
(1.55%↑ Y/Y)
Total current
liabilities
$95,586K
(10.33%↑ Y/Y)
Lease liabilities,
non-current
$58K
(-91.88%↓ Y/Y)
Common stock
$18K
(0.00%↑ Y/Y)
Loans payable, net,
current
$39,236K
(75.47%↑ Y/Y)
Revenue reserves and
refund liability
$27,974K
(-5.18%↓ Y/Y)
Accrued compensation
$8,611K
(9.04%↑ Y/Y)
Other accrued
liabilities
$7,948K
(-7.51%↓ Y/Y)
Accrued research and
development
$6,932K
(68.21%↑ Y/Y)
Accounts payable
$4,011K
(-44.98%↓ Y/Y)
Lease liabilities,
current
$656K
(26.89%↑ Y/Y)
Acquisition-related liabilities
$218K
(-95.64%↓ Y/Y)
Back
Back
Balance Sheet
RIGEL PHARMACEUTICALS INC (RIGL)
RIGEL PHARMACEUTICALS INC (RIGL)
source: myfinsight.com